6533b825fe1ef96bd1281f15

RESEARCH PRODUCT

Oocyte donation outcome after oncological treatment in cancer survivors.

Elkin MuñozMaria Elena MartinezNicolás GarridoJuan A. Garcia-velascoAntonia TocinoAntonio PellicerSusana PortelaI. Fernandez

subject

Adultmedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentMiscarriageCohort StudiesPregnancyRisk FactorsNeoplasmsmedicineHumansOvarian DiseasesSurvivorsRetrospective StudiesGynecologyPregnancyChemotherapyOocyte Donationbusiness.industryIncidenceCancer typePregnancy OutcomeObstetrics and GynecologyCancermedicine.diseaseRadiation therapyAbortion SpontaneousCausalityTreatment OutcomeReproductive MedicineSpainOocyte donationOvarian dysfunctionFemalebusinessInfertility Female

description

Objective To study reproductive outcome in patients cured of cancer who required oocyte donation (OD) owing to iatrogenic ovarian dysfunction. Design Multicenter, unmatched, retrospective cohorts study. Setting Private, university-affiliated group of clinics. Patient(s) Women treated and cured of cancer (n = 142) who underwent 333 cycles of OD (exposed group) and women without a previous cancer diagnosis (n = 17,844) who underwent 29,778 cycles of OD (unexposed cohort) between January 2000 and January 2012. Intervention(s) Retrospective chart review. Main Outcome Measure(s) Pregnancy, implantation, miscarriage, and ongoing pregnancy rates. Result(s) There were no differences in terms of pregnancy (55.7% vs. 54.7%), implantation (39.8% vs. 38.2%), miscarriage (29.5% vs. 26.9%), or delivery rates (39.3% vs. 39.9%) between the unexposed group and the patients previously diagnosed and cured of cancer, respectively. There was no correlation between OD outcome and cancer type. Conclusion(s) Endometrial receptivity in women treated and cured of cancer was comparable to that of general patients without previous malignancies who had received OD, based on the largest series available in the literature.

10.1016/j.fertnstert.2014.09.027https://pubmed.ncbi.nlm.nih.gov/25439848